Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Metabolic Dysfunction-Associated Steatohepatitis

Metabolic Dysfunction-Associated Steatohepatitis

Part of Metabolic Dysfunction-Associated Steatotic Liver Disease

Subtypes of Metabolic Dysfunction-Associated Steatohepatitis

Metabolic dysfunction-associated steatohepatitis (MASH) with significant fibrosis 1 Metabolic dysfunction-associated steatohepatitis cirrhosis 1 Non-cirrhotic metabolic dysfunction-associated steatohepatitis 1

19 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Metabolic Dysfunction-Associated Steatohepatitis

60 trials tracked for Metabolic Dysfunction-Associated Steatohepatitis: 4 in phase 3 or 4 and 2 with published results. The most-cited published study has 988 citations.

60Trials tracked
4Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 2 Phase 3 2 Phase 2 45 Phase 1 3 Other / NA 8
  1. Phase 4 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed · 988 cited
  2. Phase 4 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed · 310 cited
  3. Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis Completed
  4. Phase 3 Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH Completed
  5. Phase 2 Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) Completed
  6. Phase 2 Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy Completed
Show 44 more trials
  1. Phase 2 Pentoxifylline in Patients With Nonalcoholic Steatohepatitis Completed
  2. Phase 2 A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases Completed
  3. Phase 2 A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus Completed
  4. Phase 2 Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis Completed
  5. Phase 2 Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis Completed
  6. Phase 2 Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH) Completed
  7. Phase 2 Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) Completed
  8. Phase 2 A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH) Completed
  9. Phase 2 Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis Completed
  10. Phase 2 Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed
  11. Phase 2 A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Completed
  12. Phase 2 Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects Completed
  13. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Completed
  14. Phase 2 A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001) Completed
  15. Phase 2 Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis Completed
  16. Phase 2 BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH Completed
  17. Phase 2 Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Completed
  18. Phase 2 A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed
  19. Phase 2 Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis Completed
  20. Phase 2 CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Completed
  21. Phase 2 A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH Completed
  22. Phase 2 Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis Completed
  23. Phase 2 Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD) Completed
  24. Phase 2 Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL) Completed
  25. Phase 2 A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis Completed
  26. Phase 2 Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis Completed
  27. Phase 2 A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH Completed
  28. Phase 2 An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis Completed
  29. Phase 2 Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. Completed
  30. Phase 2 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Completed
  31. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis Completed
  32. Phase 2 Vitamin E Dosing Study Completed
  33. Phase 2 Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Completed
  34. Phase 2 Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease Completed
  35. Phase 2 A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM) Completed
  36. Phase 2 Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) Completed
  37. Phase 2 JKB-121 for the Treatment of Nonalcoholic Steatohepatitis Completed
  38. Phase 2 Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH) Completed
  39. Phase 2 A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Completed
  40. Phase 2 A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage Completed
  41. Phase 2 Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH Completed
  42. Phase 2 Phase II Trial of Silymarin for Non-Cirrhotic Patients With Non-Alcoholic Steatohepatitis Completed
  43. Phase 2 A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH Completed
  44. Phase 1 A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014) Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review synthesizes evidence on NAFLD, NASH, and viral hepatitis management without reported trial data
Allergy & Immunology Sys. Review
Narrative review synthesizes evidence on NAFLD, NASH, and viral hepatitis management without reported trial data Your Liver Has an Immune Army — and It Can Turn Against You
This narrative review addresses management considerations for nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH),…
Your liver's own immune cells can turn on itself to cause permanent scarring, but scientists are now mapping these cells to stop the damage …
Frontiers Apr 18, 2026
Review of liver disease immunomodulation strategies notes precision over broad suppression
Neurology Sys. Review
Review of liver disease immunomodulation strategies notes precision over broad suppression Your Liver's Immune Cells Play Both Hero and Villain at Once
This narrative review examines immunomodulation approaches for liver diseases, including acute liver injury, HBV infection, MASLD/MASH, fibr…
Liver immune cells can both damage and repair your organ at the same time, a discovery that could unlock new precision treatments for hepati…
Frontiers Apr 18, 2026
Meta-analysis of efruxifermin shows significant liver benefits in NASH/MASH patients with short follow-up
Drug Pipeline Meta-analysis
Meta-analysis of efruxifermin shows significant liver benefits in NASH/MASH patients with short follow-up New Drug Clears Fat and Scar From Liver
This systematic review and meta-analysis evaluated efruxifermin versus placebo in 419 patients with NASH/MASH.
A new drug helps clear fat and repair scar tissue in the liver, offering a direct fix for serious damage beyond just weight loss.
Frontiers Apr 18, 2026
Review of bile acid homeostasis regulation in liver disease and cancer
Nutrition & Obesity Medicine Sys. Review
Review of bile acid homeostasis regulation in liver disease and cancer Review of bile acid regulation for liver disease conditions shows limited evidence
This narrative review examines the regulation of bile acids homeostasis in conditions including cholestasis, hepatic fibrosis, cirrhosis, he…
Bile acid imbalance drives liver disease, but this review found no data proving that regulating it safely treats conditions like cirrhosis o…
Frontiers Apr 15, 2026
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis
Gastroenterology Meta-analysis
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis New drug ranking shows one treatment stands out for advanced fatty liver scarring
This network meta-analysis evaluated histological efficacy in patients with biopsy-proven compensated metabolic dysfunction-associated steat…
Efruxifermin is the only drug proven to shrink advanced liver scarring without worsening the disease, ranking first among new treatments for…
Apr 9, 2026
Perspective reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis
Gastroenterology
Perspective reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis Could new drugs finally treat the liver scarring of MASH?
A perspective article reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis (MASH), including metabol…
New metabolic drugs and direct liver therapies offer fresh hope for reversing the scarring that leads to dangerous cirrhosis in MASH patient…
Frontiers Apr 1, 2026
Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis
Gastroenterology Phase II
Phase 1/2a trial tests oral idebenone safety in adults with NASH and fibrosis Can an oral drug help people with fatty liver disease? Early safety study begins
A randomized, double-blinded, placebo-controlled, single-center phase 1/2a study enrolled 53 adults with NASH and stage 1-3 fibrosis to asse…
A new oral drug for fatty liver disease has finished its early safety study, with results expected soon to show if it helps stop scarring.
CT.gov Mar 30, 2026

Research across Metabolic Dysfunction-Associated Steatotic Liver Disease

Related studies from across the Metabolic Dysfunction-Associated Steatotic Liver Disease family.

MTARC1 inhibition may reduce cirrhosis and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease
Diabetes & Endocrinology Meta-analysis
MTARC1 inhibition may reduce cirrhosis and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease Blocking a liver protein could lower risks for fatty liver disease patients
This meta-analysis of data from the Quebec Obesity Biobank used integrated proteogenomic analysis and Mendelian randomization to assess caus…
A massive analysis suggests blocking a specific liver protein might reduce risks for fatty liver disease, cirrhosis, and cancer while improv…
medRxiv Jun 6, 2026
IGFBPs show dual roles in metabolic dysfunction-associated steatotic liver disease progression
Diabetes & Endocrinology Sys. Review
IGFBPs show dual roles in metabolic dysfunction-associated steatotic liver disease progression IGFBP proteins play opposite roles in liver disease progression
This narrative review synthesizes evidence on insulin-like growth factor-binding proteins (IGFBPs) in metabolic dysfunction-associated steat…
A review shows specific IGFBP proteins can protect the liver or drive damage depending on the stage of disease and which protein is involved…
Frontiers Jun 5, 2026
GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety
Gastroenterology Sys. Review
GLP-1 receptor agonists show potential benefits for metabolic dysfunction-associated steatotic liver disease with acceptable safety Review shows GLP-1 drugs may help fatty liver disease
This umbrella review evaluated twenty-three meta-analyses and systematic reviews regarding GLP-1 receptor agonists in patients with metaboli…
A review of many studies suggests GLP-1 receptor agonists may improve fatty liver disease, but the evidence is still early and needs stronge…
Frontiers May 29, 2026
Narrative review explores immunometabolic networks in MASH and MASLD
Nutrition & Obesity Medicine Sys. Review
Narrative review explores immunometabolic networks in MASH and MASLD Future treatments for fatty liver disease may use personalized networks to guide care
This narrative review discusses metabolic dysfunction-associated steatohepatitis (MASH) and steatotic liver disease (MASLD), focusing on imm…
New ideas for treating fatty liver disease focus on personalized networks and multi-target approaches to guide future drug development.
Frontiers May 27, 2026
Systematic Review of Schisandra chinensis for Metabolic Dysfunction-Associated Steatotic Liver Disease
Rheumatology Sys. Review
Systematic Review of Schisandra chinensis for Metabolic Dysfunction-Associated Steatotic Liver Disease Ancient herb shows promise for fatty liver disease
This systematic review summarizes preclinical evidence on Schisandra chinensis Fructus (SCF) and its metabolites for metabolic dysfunction-a…
A systematic review finds Schisandra chinensis may protect the liver and reduce fat buildup, but evidence is still early.
Frontiers May 17, 2026
Systematic review of Dendrobium phenanthrene bioactivity across multiple disease models
Drug Pipeline Sys. Review
Systematic review of Dendrobium phenanthrene bioactivity across multiple disease models Scientists found many plant chemicals that fight cancer and help diabetes in lab tests
This systematic review evaluates the bioactivity of 158 phenanthrene metabolites isolated from 53 Dendrobium taxa. The authors note that 64 …
A review of plant chemicals from Dendrobium plants shows strong activity against cancer and diabetes in lab studies. Most results come from …
Frontiers May 15, 2026
Pediatric Gut Microbiome Links to Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes
Gastroenterology Sys. Review
Pediatric Gut Microbiome Links to Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes Your Child's Gut Health May Protect Against Fatty Liver Disease
Current literature reveals complex associations between the pediatric gut microbiome and metabolic dysfunction-associated steatotic liver di…
• Specific gut bacteria patterns predict fatty liver risk in children • Helps parents of overweight kids with diabetes or obesity • Not read…
Frontiers May 13, 2026
Meta-analysis finds no significant difference in Lp(a) levels in MASLD patients vs controls
Nutrition & Obesity Medicine Meta-analysis
Meta-analysis finds no significant difference in Lp(a) levels in MASLD patients vs controls Popular Heart Risk Marker Fails to Predict Fatty Liver Disease
This meta-analysis of observational studies compared circulating lipoprotein(a) concentrations between adults with MASLD/NAFLD/MAFLD and con…
A common blood test for heart disease risk shows no link to fatty liver disease, disappointing hopes for a simple diagnostic tool.
Frontiers May 13, 2026
Meta-analysis shows curcumin reduces weight but lacks impact on BMI or waist circumference in metabolic fatty liver disease patients
Gastroenterology Meta-analysis
Meta-analysis shows curcumin reduces weight but lacks impact on BMI or waist circumference in metabolic fatty liver disease patients Curcumin Helps Weight But Not Waist Size In Fatty Liver
A meta-analysis of curcumin supplementation in patients with metabolic-associated fatty liver disease revealed a significant reduction in bo…
Curcumin might help you lose a few pounds but it will not shrink your waist or fix your BMI score
NEJM May 12, 2026
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease
Drug Pipeline Sys. Review
Review of triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease New Hope for Fatty Liver Disease Targets Hidden Triglyceride Problem
This narrative review synthesizes evidence on triglyceride-lowering therapies for metabolic dysfunction-associated steatotic liver disease. …
• Lowering triglycerides may directly heal fatty liver damage • Helps millions with metabolic syndrome and stubborn liver fat • Most treatme…
Frontiers May 12, 2026
Metabolic dysfunction-associated steatotic liver disease patients with advanced fibrosis face high hepatocellular carcinoma risk over ten years
Gastroenterology Meta-analysis
Metabolic dysfunction-associated steatotic liver disease patients with advanced fibrosis face high hepatocellular carcinoma risk over ten years Liver cancer risk much higher with this common condition
A massive meta-analysis of nearly four million individuals reveals stark differences in hepatocellular carcinoma development based on fibros…
Many people with fatty liver disease never know their risk of liver cancer could be rising, especially if they have undetected scarring.
May 2, 2026
Systematic review and meta-analysis assesses SWDS diagnostic accuracy for MASLD liver inflammation grading
Gastroenterology Meta-analysis
Systematic review and meta-analysis assesses SWDS diagnostic accuracy for MASLD liver inflammation grading Shear-wave dispersion slope helps doctors grade liver inflammation in metabolic disease
This systematic review and diagnostic test accuracy meta-analysis evaluates the Shear-wave dispersion slope (SWDS) for detecting and grading…
A new analysis shows a noninvasive test can accurately detect and grade liver inflammation in patients with metabolic dysfunction-associated…
May 1, 2026

Questions about Metabolic Dysfunction-Associated Steatohepatitis

Can machine learning diagnose metabolic dysfunction-associated steatohepatitis and fibrosis?

Yes, machine learning models show good accuracy for diagnosing MASH and fibrosis, with pooled AUROCs around 0.83-0.84, but they are not yet ready to replace liver biopsy in clinical practice.

Full answer →
Which drugs work best for non-cirrhotic metabolic dysfunction-associated steatohepatitis?

For non-cirrhotic MASH, drugs targeting metabolism and insulin sensitivity (e.g., tirzepatide, semaglutide) work best, but lifestyle changes and weight loss are foundational.

Full answer →
Can lowering triglycerides help treat metabolic dysfunction-associated steatohepatitis?

Yes, lowering triglycerides may help treat MASH by reducing liver fat and improving inflammation, but more research is needed to confirm long-term benefits.

Full answer →